Literature DB >> 16136504

The role of the bone marrow microenvironment in multiple myeloma.

H R De Raeve1, K Vanderkerken.   

Abstract

Multiple myeloma (MM) is a malignant disease that results from an excess of monotypic plasma cells in the bone marrow (BM). This malignancy is characterised by complex karyotypic aberrancies. In 60% of all MM there are recurrent primary translocations involving the heavy chain gene locus. The MM cells strongly interact with the BM microenvironment, which is composed of endothelial cells, stromal cells, osteoclasts, osteoblasts, immune cells, fat cells and the extracellular matrix. This interaction is responsible for the specific homing in the BM, the proliferation and survival of the MM cells, the resistance of MM cells to chemotherapy, the development of osteolysis, immunodeficiency and anaemia. New therapeutic agents target both the MM, as well as the interaction MM cell - BM microenviroment.

Entities:  

Mesh:

Year:  2005        PMID: 16136504     DOI: 10.14670/HH-20.1227

Source DB:  PubMed          Journal:  Histol Histopathol        ISSN: 0213-3911            Impact factor:   2.303


  24 in total

1.  Adipogenesis and osteoblastogenesis: trans-differentiation in the pathophysiology of bone disorders.

Authors:  Ch Savopoulos; Ch Dokos; G Kaiafa; A Hatzitolios
Journal:  Hippokratia       Date:  2011-01       Impact factor: 0.471

Review 2.  Identify multiple myeloma stem cells: Utopia?

Authors:  Ilaria Saltarella; Aurelia Lamanuzzi; Antonia Reale; Angelo Vacca; Roberto Ria
Journal:  World J Stem Cells       Date:  2015-01-26       Impact factor: 5.326

Review 3.  Dendritic cells and malignant plasma cells: an alliance in multiple myeloma tumor progression?

Authors:  Marco Tucci; Stefania Stucci; Sabino Strippoli; Franco Dammacco; Franco Silvestris
Journal:  Oncologist       Date:  2011-06-09

4.  Synchronous occurrence of prostate carcinoma and multiple myeloma: a case report.

Authors:  Tushar Sehgal; Sudha Sharma; Shano Naseem; Neelam Varma; Ashim Das; S C Sharma
Journal:  Indian J Hematol Blood Transfus       Date:  2014-06-01       Impact factor: 0.900

5.  Fibroblast activation protein protects bortezomib-induced apoptosis in multiple myeloma cells through β-catenin signaling pathway.

Authors:  Fu-Ming Zi; Jing-Song He; Yi Li; Cai Wu; Wen-Jun Wu; Yang Yang; Li-Juan Wang; Dong-Hua He; Li Yang; Yi Zhao; Gao-Feng Zheng; Xiao-Yan Han; He Huang; Qing Yi; Zhen Cai
Journal:  Cancer Biol Ther       Date:  2014-07-21       Impact factor: 4.742

6.  Towards effective immunotherapy of myeloma: enhanced elimination of myeloma cells by combination of lenalidomide with the human CD38 monoclonal antibody daratumumab.

Authors:  Michael S van der Veer; Michel de Weers; Berris van Kessel; Joost M Bakker; Shulamiet Wittebol; Paul W H I Parren; Henk M Lokhorst; Tuna Mutis
Journal:  Haematologica       Date:  2010-11-25       Impact factor: 9.941

7.  Vicious cycle between myeloma cell binding to bone marrow stromal cells via VLA-4-VCAM-1 adhesion and macrophage inflammatory protein-1alpha and MIP-1beta production.

Authors:  Masahiro Abe; Kenji Hiura; Shuji Ozaki; Shinsuke Kido; Toshio Matsumoto
Journal:  J Bone Miner Metab       Date:  2008-12-05       Impact factor: 2.626

8.  Interleukin-6 and JAK2/STAT3 signaling mediate the reversion of dexamethasone resistance after dexamethasone withdrawal in 7TD1 multiple myeloma cells.

Authors:  Tuoen Liu; Zhiqiang Fei; Kalyan J Gangavarapu; Senyo Agbenowu; Alok Bhushan; James C K Lai; Christopher K Daniels; Shousong Cao
Journal:  Leuk Res       Date:  2013-07-18       Impact factor: 3.156

Review 9.  Immune responses in multiple myeloma: role of the natural immune surveillance and potential of immunotherapies.

Authors:  Camille Guillerey; Kyohei Nakamura; Slavica Vuckovic; Geoffrey R Hill; Mark J Smyth
Journal:  Cell Mol Life Sci       Date:  2016-01-22       Impact factor: 9.261

Review 10.  Multiple myeloma in the marrow: pathogenesis and treatments.

Authors:  Heather Fairfield; Carolyne Falank; Lindsey Avery; Michaela R Reagan
Journal:  Ann N Y Acad Sci       Date:  2016-01       Impact factor: 5.691

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.